Association of pretreatment amlodipine and outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

سال انتشار: 1402
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 90

فایل این مقاله در 8 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_CBJ-3-1_001

تاریخ نمایه سازی: 7 شهریور 1402

چکیده مقاله:

Objectives: The current study is a retrospective cross-sectional study that reviewed ۴۹۷ patients with an ST-elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI). Demographic data including age, gender, history of Hypertension (HTN), diabetes mellitus, and smoking and data related to the use of Amlodipine, pic of cardiac troponin I (cardiac enzyme), ejection fraction (EF), arrhythmia at the admission, and death after PCI extracted from the previous file. The patients were divided into two groups, the first group with a history of taking amlodipine and the second group without a history of taking amlodipine. SPSS version ۲۶ was used for data analysis. T-tests, chi-square, and Fisher's exact were used to test the relationship between variables.Methods: In this retrospective cross-sectional study, the medical records of ۴۹۷ patients with STEMI who underwent PCI were reviewed. The data were age, gender, previous use of Amlodipine, pic of cardiac troponin I (CINI), (EF), arrhythmia at the admission, history of HTN, Diabetes mellitus and smoking, and death after PCI. Then patients were divided into two groups with (group ۱) or without (group ۲) a history of Amlodipine use. Student t-test, chi-square test, and the Fisher exact test were applied to investigate the associations between variables using the SPSS version ۲۶.Results: Out of ۴۹۷ patients included, ۸۱.۳% were males with a mean age of ۵۸.۷±۱۲.۰۲ years, and ۲۲.۷% had a history of taking amlodipine. Patients in group ۲ showed more death and MI than group ۱ (OR = ۱.۳۲ [۹۵% CI, ۱.۲۵-۱.۳۹], P=۰.۰۰۲) and (OR=۳.۹۳ [۹۵% CI, ۲.۲۴-۶.۸۷], P<۰.۰۰۱). There were no differences between the two groups in terms of age, sex, cTnI, EF, rate of arrhythmia, the pattern of vascular involvement, kind of vascular involvement, and occlusion location (P= ۰.۶, ۰.۹, ۰.۰۹, ۰.۱, ۰.۳, ۰.۲۸, ۰.۲۹ and ۰.۸, respectively).Conclusions: Amlodipine administered before MI significantly reduced the mortality rate after PCI compared to patients not taking amlodipine. The result can be attributed to the antioxidant effect, limiting the consequences of injury around reperfusion.

نویسندگان

Haleh Bodagh

Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Ahmad Separham

Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Shokoufeh khanzadeh

Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Leila Vahedi

Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Elaheh Mohtadifar

Student Research Committee, Islamic Azad University of Tabriz, Iran

Mohammad bagher Bodage

Student Research Committee, Islamic Azad University of Tabriz, Iran

Razieh Parizad

Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Roth GA, Mensah GA, Johnson CO, et al. Global burden ...
  • Mills KT, Stefanescu A, He J.The Global epidemiology of hypertension. ...
  • Cappuccio FP, Miller MA. Cardiovascular disease and hypertension in sub-saharan ...
  • Ataklte F, Erqou S, Kaptoge S, et al. Burden of ...
  • Bundy JD, He J. Hypertension and related cardiovascular disease burden ...
  • St-Onge M, Dubé P-A, Gosselin S, et al. Treatment for ...
  • Godfraind T. Discovery and development of calcium channel blockers. Front ...
  • Wright JM, Musini VM, Gill R. First‐line drugs for hypertension. ...
  • Tocci G, Battistoni A, Passerini J, et al. Calcium channel ...
  • Maor E, Eleid MF, Gulati R, et al. Current and ...
  • Silber S, Albertsson P, Avilés FF, et al. Guidelines for ...
  • Sheraz MA, Ahsan SF, Khan MF, et al. Formulations of ...
  • Costanzo P, Perrone-Filardi P, Petretta M, et al. Calcium channel ...
  • Nishigaki K, Inoue Y, Yamanouchi Y, et al. Prognostic effects ...
  • Dunlap ED, Matlib MA, Millard RW. Protection of regional mechanics ...
  • L H Opie. Reperfusion injury and its pharmacologic modification. Circulation. ...
  • Jørgensen B, Simonsen S, Endresen K, et al. Restenosis and ...
  • Dens JA, Desmet WJ, Coussement P, et al. Usefulness of ...
  • O'Keefe Jr JH, Giorgi LV, Hartzler GO, et al. Effects ...
  • Kloner RA, Braunwald E. Effects of calcium antagonists on infarcting ...
  • Masoumi S, Separham A, Parizad R, et al. Dual Left ...
  • Parsons RW, Hung J, Hanemaaijer I, et al. Prior calcium ...
  • Hagar JM, Newman LG, Kloner RA. Effects of amlodipine on ...
  • Jørgensen B, Thaulow E. Effects of amlodipine on ischemia after ...
  • Gulmez O, Atar I, Ozin B, et al. The effects ...
  • Sandmann S, Claas R, Cleutjens JP, et al. Calcium channel ...
  • Ashraf H, Soltani D, Sobh-Rakhshankhah A, et al.Visfatin as marker ...
  • Corcos T, David PR, Val PG, et al. Failure of ...
  • نمایش کامل مراجع